2014 - Transplant Infectious Disease Conference


Multidrug resistant bacteria in solid organ transplant recipients

3.2 - Optimising anti-bacterial therapy; do we underdose and set the scene for resistance?

Presenter: Jason, Roberts, Brisbane, Australia
Authors: Jason Roberts


Transplant patients, like trauma, burns and critically ill patients, can develop dramatically altered pharmacokinetics (antibacterial concentrations) leading to altered pharmacodynamics (antibacterial effects, e.g. bacterial killing). Part of these altered effects may be sub-optimal rates of bacterial eradication which can predispose to the development of sub-populations of resistant pathogens leading to greater patient morbidity and potentially mortality. Minimising the emergence of antibiotic resistance may be achieved through optimized antibacterial therapy. In this presentation, the issues surrounding the emergence of resistance associated with sub-optimal dosing will be discussed as well as some key points related to optimizing dosing of specific antibiotic agents.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi